Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTR Nektar Therapeutics

Pre-Mkt 04-10 08:46:03 EDT

77.85

+2.77

+3.69%

盘前77.73

-0.12-0.15%

08:42 EDT

High77.99	Low74.79	Vol456.48K
Open74.95	D1 Closing75.08	Amplitude4.26%
Mkt Cap2.23B	Tradable Cap2.04B	Total Shares28.69M
T/O35.22M	T/O Rate1.74%	Tradable Shares26.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"Nektar Therapeutics","latestPrice":77.85,"timestamp":1775764800000,"preClose":75.08,"halted":0,"volume":456475,"hourTrading":{"tag":"盘前","latestPrice":77.73,"preClose":77.85,"latestTime":"08:42 EDT","volume":1100,"amount":85643.239,"timestamp":1775824922886,"change":-0.12,"changeRate":-0.001541,"amplitude":0.006294},"delay":0,"changeRate":0.03689397975492802,"floatShares":26240400,"shares":28688000,"eps":-9.73,"marketStatus":"Pre-Mkt","change":2.77,"latestTime":"04-10 08:46:03 EDT","open":74.95,"high":77.99,"low":74.79,"amount":35223601.231,"amplitude":0.042621,"askPrice":78,"askSize":100,"bidPrice":76.38,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-9.73,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775827800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":77.85,"preHourTrading":{"tag":"盘前","latestPrice":77.73,"preClose":77.85,"latestTime":"08:42 EDT","volume":1100,"amount":85643.239,"timestamp":1775824922886,"change":-0.12,"changeRate":-0.001541,"amplitude":0.006294},"postHourTrading":{"tag":"盘后","latestPrice":77.85,"preClose":77.85,"latestTime":"19:00 EDT","volume":4924,"amount":383270.815,"timestamp":1775775653140,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6435604759086233,"impliedVol":0.8707,"impliedVolPercentile":0.3548},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"2626315488","title":"A Look At Nektar Therapeutics (NKTR) Valuation After Rezpegaldesleukin Trial Progress And Litigation Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2626315488","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626315488?lang=en_us&edition=fundamental","pubTime":"2026-04-10 07:35","pubTimestamp":1775777722,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) is back in focus after new Phase 2b data for rezpegaldesleukin in atopic dermatitis and alopecia areata at the 2026 American Academy of Dermatology meeting, alongside ongoing securities litigation tied to earlier trial conduct.\nSee our latest analysis for Nektar Therapeutics.\nRezpegaldesleukin’s new Phase 2b data and plans for a Phase 3 atopic dermatitis program arrive after a sharp swing in sentiment, with a 90 day share price return of 96.05% and a very large 1...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/a-look-at-nektar-therapeutics-nktr-valuation-after-rezpegald","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/a-look-at-nektar-therapeutics-nktr-valuation-after-rezpegald","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","PRGS","BK4007","NKTR","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625239953","title":"Nektar Therapeutics (NKTR) Receives a Buy from Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2625239953","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625239953?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:47","pubTimestamp":1775566066,"startTime":"0","endTime":"0","summary":"In a report released today, Samantha Semenkow from Citi reiterated a Buy rating on Nektar Therapeutics, with a price target of $123.00. Semenkow co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nektar-therapeutics-nktr-receives-a-buy-from-citi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nektar-therapeutics-nktr-receives-a-buy-from-citi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625648703","title":"Do Rezpegaldesleukin Lawsuits Reframe Nektar Therapeutics' (NKTR) Core Risk Narrative Around Trial Integrity?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625648703","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625648703?lang=en_us&edition=fundamental","pubTime":"2026-04-05 11:23","pubTimestamp":1775359387,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics recently presented Phase 2b data for its T‑reg–enhancing biologic rezpegaldesleukin in atopic dermatitis and alopecia areata at the 2026 American Academy of Dermatology meeting, while also advancing plans for a Phase 3 atopic dermatitis program and highlighting prior Fast Track designations from the FDA.\nAt the same time, multiple law firms have launched or promoted securities class actions alleging protocol violations and misleading disclosures in the REZOLVE-AA alopecia...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/do-rezpegaldesleukin-lawsuits-reframe-nektar-therapeutics-nk","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/do-rezpegaldesleukin-lawsuits-reframe-nektar-therapeutics-nk","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AA","BK4007","NKTR","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624657013","title":"Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Stock Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2624657013","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624657013?lang=en_us&edition=fundamental","pubTime":"2026-04-03 20:33","pubTimestamp":1775219617,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics ($NKTR) told investors its REZOLVE-AA trial followed stated eligibility criteria and protocol standards. Executives repeatedly ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/nektar-therapeutics-faces-investor-lawsuit-over-alleged-clinical-trial-enrollment-failures-and-stock-decline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/nektar-therapeutics-faces-investor-lawsuit-over-alleged-clinical-trial-enrollment-failures-and-stock-decline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","AA","BK4153","BK4007","LU2543165471.USD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623354697","title":"Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2623354697","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623354697?lang=en_us&edition=fundamental","pubTime":"2026-03-29 23:40","pubTimestamp":1774798807,"startTime":"0","endTime":"0","summary":"Nektar (NKTR) Therapeutics showcased data in two presentations at the 2026 American Academy of Dermatology, AAD, Annual Meeting taking place in Den...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-announces-data-from-phase-2b-rezolve-ad-rezolve-aa-studies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-announces-data-from-phase-2b-rezolve-ad-rezolve-aa-studies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AD","LU2543165471.USD","NKTR","BK4588","BK4153","AA","BK4132","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623387895","title":"Nektar plans Phase 3 ZENITH-AD program after rezpegaldesleukin Phase 2b results","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387895","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623387895?lang=en_us&edition=fundamental","pubTime":"2026-03-29 00:36","pubTimestamp":1774715783,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics presented Phase 2b data at 2026 American Academy of Dermatology meeting for rezpegaldesleukin in moderate-to-severe atopic dermatitis.REZOLVE-AD study enrolled 393 patients, showing statistically significant improvement in mean percent EASI improvement versus placebo across baseline vIGA-AD severity 3 or 4.Trial also reported comparable EASI-75 and EASI-90 response rates during 16-week induction period across moderate and severe subgroups.Separate late-breaking oral presentation highlighted Phase 2b REZOLVE-AA results in severe-to-very-severe alopecia areata at 36 weeks.High-dose rezpegaldesleukin 24 g/kg every two weeks cut mean SALT score 28.2% versus 11.2% for placebo; Nektar plans to start Phase 3 ZENITH-AD program in second quarter 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL4MdTZz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622381094","title":"Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2622381094","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622381094?lang=en_us&edition=fundamental","pubTime":"2026-03-25 00:41","pubTimestamp":1774370470,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) promoted rezpegaldesleukin as a promising drug candidate and described the REZOLVE-AA study’s enrollment criteria and tr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/nektar-therapeutics-faces-investor-lawsuit-over-alleged-clinical-trial-enrollment-failures-and-misleading-disclosures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/nektar-therapeutics-faces-investor-lawsuit-over-alleged-clinical-trial-enrollment-failures-and-misleading-disclosures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4153","BK4588","LU2543165471.USD","BK4585","BK4007","NKTR","AA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621509355","title":"Nektar Therapeutics Initiated at Neutral by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2621509355","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621509355?lang=en_us&edition=fundamental","pubTime":"2026-03-24 22:14","pubTimestamp":1774361640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 10:14 ET (14:14 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621069117","title":"Nektar initiated with a Neutral at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069117","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069117?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:15","pubTimestamp":1774350928,"startTime":"0","endTime":"0","summary":"Wedbush initiated coverage of Nektar (NKTR) with a Neutral rating and $70 price target The firm believes the company’s ongoing trials in alopecia a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-initiated-with-a-neutral-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-initiated-with-a-neutral-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621066019","title":"Wedbush Initiates Nektar Therapeutics at Neutral With $70 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2621066019","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621066019?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:05","pubTimestamp":1774350326,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) has an average rating of buy and mean price target of $136.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621325940","title":"A Look At Nektar Therapeutics (NKTR) Valuation As Rezpegaldesleukin Data Heads To Major Dermatology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2621325940","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621325940?lang=en_us&edition=fundamental","pubTime":"2026-03-24 10:09","pubTimestamp":1774318194,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) is back in focus after announcing that Phase 2b data for its lead candidate, rezpegaldesleukin, in atopic dermatitis and alopecia areata will be featured in two oral presentations at the 2026 American Academy of Dermatology meeting.\nSee our latest analysis for Nektar Therapeutics.\nThe rezpegaldesleukin update lands after a sharp turnaround in sentiment, with a 90 day share price return of 67.21% and a 1 year total shareholder return of almost 5x despite a weak 2025...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/a-look-at-nektar-therapeutics-nktr-valuation-as-rezpegaldesl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/a-look-at-nektar-therapeutics-nktr-valuation-as-rezpegaldesl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620734565","title":"Nektar rezpegaldesleukin Phase 2b data set for two oral presentations at AAD annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620734565","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620734565?lang=en_us&edition=fundamental","pubTime":"2026-03-20 22:00","pubTimestamp":1774015247,"startTime":"0","endTime":"0","summary":"Nektar will attend the American Academy of Dermatology Annual Meeting on March 27-31, 2026 in Denver, Colorado.Data from a Phase 2b study of rezpegaldesleukin in severe-to-very-severe alopecia areata will be presented on March 28, 2026 from 10:36-10:48 AM MST at the Colorado Convention Center .Phase 2b data for rezpegaldesleukin in moderate-to-severe atopic dermatitis will be presented on March 28, 2026 from 11:40-11:45 AM MST at the Colorado Convention Center .","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDLZR438:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620942347","title":"Nektar Therapeutics: Rezpeg Clinical Momentum and Strong Cash Runway Underscore Attractive Risk‑Reward at Current Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942347","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620942347?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:15","pubTimestamp":1773742523,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Arthur He CFA has maintained their bullish stance on NKTR stock, giving a Buy rating today. Arthur He CFA has given his Buy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nektar-therapeutics-rezpeg-clinical-momentum-and-strong-cash-runway-underscore-attractive-risk‑reward-at-current-levels-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nektar-therapeutics-rezpeg-clinical-momentum-and-strong-cash-runway-underscore-attractive-risk‑reward-at-current-levels-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CFA","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620428220","title":"Nektar initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2620428220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620428220?lang=en_us&edition=fundamental","pubTime":"2026-03-17 17:45","pubTimestamp":1773740728,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Marc Frahm initiated coverage of Nektar (NKTR) with a Buy rating and no price target The company is developing immunotherapies for...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","TD","BK4007","BK4585","BK4127","COWN","BK4566","BK4207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620428854","title":"Nektar Therapeutics : TD Cowen Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620428854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620428854?lang=en_us&edition=fundamental","pubTime":"2026-03-17 17:38","pubTimestamp":1773740313,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nFWN4040QQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620246051","title":"Nektar Therapeutics Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2620246051","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620246051?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:47","pubTimestamp":1773679620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 12:47 ET (16:47 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619149111","title":"Nektar Therapeutics Bets Big on Respag Phase 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2619149111","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619149111?lang=en_us&edition=fundamental","pubTime":"2026-03-14 08:04","pubTimestamp":1773446678,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (($NKTR)) has held its Q4 earnings call. Read on for the main highlights of the call. Nektar Therapeutics’ latest earnings call...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-bets-big-on-respag-phase-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-bets-big-on-respag-phase-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131410982","title":"Stock Track | Nektar Therapeutics Soars 5.45% Intraday on Analyst Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=1131410982","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131410982?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:33","pubTimestamp":1773408838,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) saw its stock price soar 5.45% during intraday trading on Friday, reflecting significant positive momentum.The surge appears to be driven by renewed analyst confidence in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619557881","title":"Nektar Therapeutics Q4 Swings to Loss, Revenue Declines","url":"https://stock-news.laohu8.com/highlight/detail?id=2619557881","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619557881?lang=en_us&edition=fundamental","pubTime":"2026-03-13 04:31","pubTimestamp":1773347503,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics  reported a Q4 loss late Thursday of $1.78 per diluted share, swinging from earnings of $0.52 a year earlier.Analysts surveyed by FactSet expected a loss of $2.47.Revenue for the three months ended Dec. 31 was $21.8 million, down from $29.2 million a year earlier.Analysts polled by FactSet expected $10.2 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619155206","title":"Earnings Flash (NKTR) Nektar Therapeutics Posts Q4 Loss Per Share $1.78, vs. FactSet Est of $2.47 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2619155206","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619155206?lang=en_us&edition=fundamental","pubTime":"2026-03-13 04:27","pubTimestamp":1773347257,"startTime":"0","endTime":"0","summary":"Earnings Flash (NKTR) Nektar Therapeutics Posts Q4 Loss Per Share $1.78, vs. FactSet Est of $2.47 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":0.0112},{"period":"1month","weight":0.0802},{"period":"3month","weight":0.9605},{"period":"6month","weight":0.4326},{"period":"1year","weight":9.1645},{"period":"ytd","weight":0.8413}],"compareEarnings":[{"period":"1week","weight":0.0367},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0204},{"period":"6month","weight":0.0412},{"period":"1year","weight":0.2393},{"period":"ytd","weight":-0.0029}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.029488},{"month":3,"riseRate":0.40625,"avgChangeRate":-0.000642},{"month":4,"riseRate":0.46875,"avgChangeRate":0.013781},{"month":5,"riseRate":0.354839,"avgChangeRate":0.003107},{"month":6,"riseRate":0.40625,"avgChangeRate":0.024924},{"month":7,"riseRate":0.4375,"avgChangeRate":-0.019557},{"month":8,"riseRate":0.46875,"avgChangeRate":0.044887},{"month":9,"riseRate":0.5,"avgChangeRate":0.042479},{"month":10,"riseRate":0.375,"avgChangeRate":-0.023288},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"Nektar Therapeutics","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nektar Therapeutics,NKTR,Nektar Therapeutics股票,Nektar Therapeutics股票老虎,Nektar Therapeutics股票老虎国际,Nektar Therapeutics行情,Nektar Therapeutics股票行情,Nektar Therapeutics股价,Nektar Therapeutics股市,Nektar Therapeutics股票价格,Nektar Therapeutics股票交易,Nektar Therapeutics股票购买,Nektar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction